Search results for "Lewy body disease"

showing 10 items of 14 documents

Neurodegeneration in tauopathies and synucleinopathies.

2016

International audience; While increasing life expectancy is a major achievement, the global aging of societies raises a number of medical issues, such as the development of age-related disorders, including neurodegenerative diseases. The three main disease groups constituting the majority of neurodegenerative diseases are tauopathies, alpha-synucleinopathies and diseases due to repetitions of glutamine (including Huntington's disease). In each neurodegenerative disease, the accumulation of one or more aggregated proteins has been identified as the molecular signature of the disease (as seen, for example, in Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, amyotrophic lat…

0301 basic medicineLewy Body DiseaseParkinson's disease[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologyParkinson's diseaseDementia with Lewy bodiesMédecine humaine et pathologieDiseaseBioinformatics03 medical and health scienceschemistry.chemical_compound0302 clinical medicineParkinsonian Disorders[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyMedicineDementiaHumansCytoskeletonSynucleinopathiesAlpha-synucleinInclusion Bodiesbusiness.industryDementia with Lewy bodiesNeurodegenerative diseasesNeurodegenerationassociationBrainNeurodegenerative DiseasesAlzheimer's diseasemedicine.disease3. Good health030104 developmental biologyNeurologychemistryTauopathies[ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologyNerve Degenerationalpha-SynucleinDementiapathologyNeurology (clinical)businessNeuroscience030217 neurology & neurosurgery[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFrontotemporal dementiadementiaRevue neurologique
researchProduct

Validation study of the Italian Addenbrooke’s Cognitive Examination Revised in a young-old and old-old population

2011

<i>Aims:</i> The main aims of the study were the translation and the subsequent validation in Italian of the Addenbrooke’s Cognitive Examination Revised (ACE-R), and the evaluation of its usefulness in discriminating cognitively normal subjects from patients with mild dementia in an elderly population. <i>Methods:</i> The ACE-R was translated and adapted into Italian. The Italian ACE-R was administered to a group of 179 elderly subjects (72 cognitively healthy and 107 subjects with mild dementia, mean age 75.4 ± 6.4 years). The group was stratified into two subsamples according to age, i.e. a young-old (<75 years) and an old-old (≧75 years) group, in order to eval…

GerontologyCross-Cultural ComparisonLewy Body DiseaseMaleValidation studyPsychometricsPsychometricsCognitive NeurosciencePopulationNeuropsychological TestsElderlyCognitive assessmentAlzheimer DiseaseReference ValuesHumansDementia diagnosisCognitive DysfunctionAddenbrooke’s cognitive examination; Elderly; Dementia; Cognitive assessment; Young-old; Old-oldeducationAgedAged 80 and overeducation.field_of_studyAddenbrooke’s cognitive examinationDementia VascularReproducibility of ResultsTranslatingAddenbrooke's cognitive examinationPsychiatry and Mental healthItalyReference valuesFrontotemporal DementiaAddenbrooke’s cognitive examination Elderly Dementia Cognitive assessment Young-old Old-oldSettore MED/26 - NeurologiaFemaleDementiaYoung-oldOld-oldCognitive Assessment SystemGeriatrics and GerontologyPsychologyLewy body diseaseMental Status Schedule
researchProduct

Accuracy of the clinical diagnosis of dementia with Lewy bodies (DLB) among the Italian Dementia Centers: a study by the Italian DLB study group (DLB…

2022

Introduction: Dementia with Lewy bodies (DLB) may represent a diagnostic challenge, since its clinical picture overlaps with other dementia. Two toolkits have been developed to aid the clinician to diagnose DLB: the Lewy Body Composite Risk Score (LBCRS) and the Assessment Toolkit for DLB (AT-DLB). We aim to evaluate the reliability of these two questionnaires, and their ability to enhance the interpretation of the international consensus diagnostic criteria. Methods: LBCRS and AT-DLB were distributed to 135 Italian Neurological Centers for Cognitive Decline and Dementia (CDCDs), with the indication to administer them to all patients with dementia referred within the subsequent 3 months. We…

Lewy Body DiseaseClinical diagnosiDementia with Lewy bodieConsensus criteriaDementia with Lewy bodiesDermatologybehavioral disciplines and activitiesDiagnostic accuracyDiagnosis DifferentialAlzheimer DiseaseDiagnosismental disordersHumansReproducibility of ResultsDiagnostic toolkitGeneral MedicineClinical diagnosis; Cognitive impairment; Consensus criteria; Dementia; Dementia with Lewy bodies; Diagnostic accuracy; Diagnostic toolkitsClinical diagnosisnervous system diseasesSettore MED/26 - NEUROLOGIAPsychiatry and Mental healthCognitive impairmentItalyDifferentialDiagnostic toolkitsDementiaNeurology (clinical)
researchProduct

DCTN1 mutation analysis in Italian patients with PSP, MSA, and DLB

2020

Abstract DCTN1 encodes the largest subunit of dynactin complex essential in the retrograde axonal transport and cytoplasmic transport of vesicles; mutations in DCTN1 have been reported predominantly in individuals with Perry syndrome and, recently, in patients with progressive supranuclear palsy. Our genetic screening of DCTN1 in 79 patients with progressive supranuclear palsy, 100 patients with multiple system atrophy, and 28 patients with dementia with Lewy bodies from Italy revealed only synonymous and intronic variants, suggesting that DCTN1 mutations do not have a key role in the development of atypical parkinsonism in the Italian population.

Lewy Body DiseaseMale0301 basic medicineAgingPathologymedicine.medical_specialtyDementia with Lewy bodieDNA Mutational AnalysisDynactinProgressive supranuclear palsy03 medical and health sciences0302 clinical medicineAtrophymedicineHumansIn patientGenetic TestingGenetic Association StudiesAgedDCTN1Dementia with Lewy bodiesbusiness.industryProgressive supranuclear palsyGeneral NeuroscienceParkinson DiseaseDynactin ComplexMiddle AgedMultiple System Atrophymedicine.diseaseDCTN1030104 developmental biologyItalyMutation testingDynactinAxoplasmic transportDCTN1; Dementia with Lewy bodies; Dynactin; Multiple system atrophy; Progressive supranuclear palsyFemaleSupranuclear Palsy ProgressiveNeurology (clinical)Geriatrics and GerontologybusinessNegative Results030217 neurology & neurosurgeryDevelopmental BiologyNeurobiology of Aging
researchProduct

Survival time and differences between dementia with Lewy bodies and Alzheimer’s disease following diagnosis: a meta-analysis of longitudinal studies.

2019

Objective: To synthesize the evidence across longitudinal studies comparing survival in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Methods: We conducted a systematic review and meta-analysis of studies comparing survival in clinically diagnosed DLB to AD. Longitudinal cohort studies were identified through a systematic search of major electronic databases from inception to May 2018. A random effects meta-analysis was performed to calculate survival time and relative risk of death. Results: Overall, 11 studies were identified including 22,952 patients with dementia: 2029 with DLB (mean diagnosis age 76.3; 47% female) compared with 20,923 with AD (mean diagnosis age 77.2; 6…

Lewy Body DiseaseMale0301 basic medicineAgingmedicine.medical_specialtyDiseaseBiochemistryLewy bodie03 medical and health sciences0302 clinical medicineA meta-analysis of longitudinal studies.- Ageing research reviews cilt.50 ss.72-80 2019 [MUELLER C. Soysal P. RONGVE A. ISIK A. THOMPSON T. MAGGI S. SMITH L. Basso C. STEWART R. BALLARD C. et al. -Survival time and differences between dementia with Lewy bodies and Alzheimer-s disease following diagnosis]Alzheimer DiseaseInternal medicinemental disordersmedicineHumansDementiaLongitudinal StudiesLongitudinal cohortMortalityMolecular BiologyAgedDementia with Lewy bodiesbusiness.industryCognitive scoreAlzheimer's diseaseRandom effects modelmedicine.diseaseSurvival RateObservational Studies as Topic030104 developmental biologyNeurologyMeta-analysisRelative riskFemaleDementiabusinessLewy bodiesAlzheimer’s disease030217 neurology & neurosurgeryBiotechnology
researchProduct

Neuropsychiatric symptoms in 921 elderly subjects with dementia: a comparison between vascular and neurodegenerative types.

2008

Objective:  i) to describe the neuropsychiatric profile of elderly subjects with dementia by comparing vascular (VaD) and degenerative dementias, i.e. dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD); ii) to assess whether the severity and type of dementia are associated with clinically relevant neuropsychiatric symptoms (CR-NPS). Method:  One hundred and thirty-one out-patients with VaD, 100 with DLB and 690 with AD were studied. NPS were evaluated by the neuropsychiatric inventory (NPI). Results:  Vascular dementia had lower total and domain-specific NPI scores and a lower frequency of CR-NPS than AD and DLB, for which frequency of CR-NPS increased significantly with disease s…

Lewy Body DiseaseMalemedicine.medical_specialtyPathologyPsychometricsDiseaseNeuropsychological TestsCentral nervous system diseaseDegenerative diseaseAlzheimer DiseaseInternal medicinemental disordersmedicineDementiaHumansVascular dementiaAgedAged 80 and overLewy bodyDementia with Lewy bodiesDementia Vasculartechnology industry and agricultureReproducibility of Resultsneuropsychiatric symptoms vascular dementia dementia with Lewy bodies Alzheimer’s disease dementia severitymedicine.diseasePsychiatry and Mental healthnervous systemDisease ProgressionSettore MED/26 - NeurologiaFemaleAlzheimer's diseasePsychologyActa psychiatrica Scandinavica
researchProduct

False memories in Lewy-body disease.

2015

Recently, de Boysson et al. (2011) [de Boysson, C., et al. (2011). False recognition in Lewy-body disease and frontotemporal dementia. Brain and Cognition, 75, 111-118.] found that patients with Lewy-body disease (LBD) showed significantly lower rates of false memories than healthy controls, using the Deese¿Roediger¿McDermott (DRM) experimental procedure. Given that this result could be explained by the practically null rate of true recognition in the LBD group (0.09), we decided to replicate the study by de Boysson et al. (2011), but including a new condition that would maximize the true recognition rate (and analyze its effect on the rate of false memories). Specifically, in a DRM experim…

Lewy Body DiseaseMalemedicine.medical_specialtyWithin personRepression PsychologyFalse memoryAudiologyNeuropsychological TestsDevelopmental psychologyArts and Humanities (miscellaneous)MemoryDevelopmental and Educational PsychologymedicineHumansGeneral PsychologyAgedAged 80 and overNull (mathematics)General MedicineFalse recognitionTrastorns de la memòria en la vellesaFemaleLewy body diseaseOlder peoplePsychologyWord (group theory)Scandinavian journal of psychology
researchProduct

Nasal chemosensory tests: biomarker between dementia with Lewy bodies and Parkinson disease dementia.

2020

BACKGROUND: Dementia with Lewy bodies (DLB) and Parkinson disease dementia (PDD) are progressive and disabling neurodegenerative disorders, which are often misdiagnosed due to theirs overlapping clinical and paraclinical features. Nevertheless, their adequate management requires an accurate differential diagnosis. The main aim of this study was to investigate the usefulness of olfactory and trigeminal nasal testing for the differential diagnosis between DLB and PDD. METHODS: Odor thresholds to three odorants differentially activating the olfactory and trigeminal systems were assessed in patients with DLB, PDD and healthy controls (n = 20 per group). RESULTS: Odor thresholds were significant…

Lewy Body Diseasemedicine.medical_specialtyDiseasebehavioral disciplines and activitiesGastroenterologyDiagnosis Differential03 medical and health sciences0302 clinical medicineInternal medicinemental disordersmedicineDementiaHumansIn patient030223 otorhinolaryngologyCanonical discriminant analysisDetection thresholdDementia with Lewy bodiesbusiness.industryParkinson DiseaseGeneral Medicinemedicine.diseasenervous system diseasesSmellOtorhinolaryngologyBiomarker (medicine)Differential diagnosisbusinessBiomarkersRhinology
researchProduct

Analysis of the LRP10 gene in patients with Parkinson's disease and dementia with Lewy bodies from Southern Italy

2020

Recently, the LRP10 gene has been associated with Parkinson's disease (PD), Parkinson's disease with dementia (PDD), and dementia with Lewy bodies (DLB). The aim of the present study was to evaluate the presence of mutations of the LRP10 gene in patients with PD or DLB from Southern Italy. Sequencing analysis revealed only 2 missense and 3 synonymous variants in patients and control subjects and a rare variant p.L622F in a PD case. These results suggest that LRP10 mutations are not a frequent cause of PD and DLB in Southern Italy.

Lewy Body Diseasemedicine.medical_specialtyNeurologyParkinson's diseaseLRP10 . Parkinson’s disease . Dementia with Lewy bodiesDermatologyDiseasebehavioral disciplines and activities03 medical and health sciences0302 clinical medicineAlzheimer DiseaseInternal medicineDementia with Lewy bodies; LRP10; Parkinson's disease.mental disordersmedicineDementiaMissense mutationHumans030212 general & internal medicineNeuroradiologyDementia with Lewy bodiesbusiness.industryParkinson DiseaseGeneral Medicinemedicine.diseasenervous system diseasesPsychiatry and Mental healthItalyMutationSettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerybusiness030217 neurology & neurosurgery
researchProduct

Presence phenomena in parkinsonian disorders: Phenomenology and neuropsychological correlates.

2020

Introduction The feeling of a presence that occurs in the absence of objectively identifiable stimuli is common in parkinsonian disorders. Although previously considered benign and insignificant, recent evidence suggests that presence phenomena may act as the gateway to more severe hallucinations and dementia. Despite this, we still know relatively little about these phenomena. Objective To examine parkinsonian disorder patients' subjective experience of presence phenomena, and retrospectively analyse their cognitive correlates, in order to elucidate the emergence of information processing deficits in parkinsonian disorders. Methods/design 25 patients who endorsed presence phenomena were as…

Lewy Body Diseasemedicine.medical_specialtyParkinson's diseaseHallucinationsmedia_common.quotation_subjectAudiologyNeuropsychological TestsVisual processingParkinsonian DisordersmedicineDementiaHumansmedia_commonRetrospective StudiesDementia with Lewy bodiesNeuropsychologyCognitionParkinson Diseasemedicine.diseasePsychiatry and Mental healthFeelingAnxietyGeriatrics and Gerontologymedicine.symptomPsychologyCognition DisordersInternational journal of geriatric psychiatryREFERENCES
researchProduct